Mostrar el registro sencillo del ítem

dc.contributor.authorGonzález-Romero, E.
dc.contributor.authorMartínez-Valiente, C.
dc.contributor.authorGarcía-García, G.
dc.contributor.authorRosal Vela, Antonio 
dc.contributor.authorMillán, J.M.
dc.contributor.authorSanz, M.A.
dc.contributor.authorSanz, G.
dc.contributor.authorLiquori, A.
dc.contributor.authorCervera, J.V.
dc.contributor.authorVázquez-Manrique, R.P.
dc.contributor.otherBiomedicina, Biotecnología y Salud Públicaes_ES
dc.date.accessioned2024-05-08T07:39:57Z
dc.date.available2024-05-08T07:39:57Z
dc.date.issued2023
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10498/32128
dc.description.abstractAcute myeloid leukemia is a complex heterogeneous disease characterized by the clonal expansion of undifferentiated myeloid precursors. Due to the difficulty in the transfection of blood cells, several hematological models have recently been developed with CRISPR/Cas9, using viral vectors. In this study, we developed an alternative strategy in order to generate CRISPR constructs by fusion PCR, which any lab equipped with basic equipment can implement. Our PCR-generated constructs were easily introduced into hard-to-transfect leukemic cells, and their function was dually validated with the addition of MYBL2 and IDH2 genes into HEK293 cells. We then successfully modified the MYBL2 gene and introduced the R172 mutation into the IDH2 gene within NB4 and HL60 cells that constitutively expressed the Cas9 nuclease. The efficiency of mutation introduction with our methodology was similar to that of ribonucleoprotein strategies, and no off-target events were detected. Overall, our strategy represents a valid and intuitive alternative for introducing desired mutations into hard-to-transfect leukemic cells without viral transduction.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI)es_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.sourceCancers, Vol. 15, Núm. 17, 2023es_ES
dc.subjectfusion PCRes_ES
dc.subjecthard-to-transfect cell lineses_ES
dc.subjectleukemiaes_ES
dc.subjectsgRNA constructses_ES
dc.titlePCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lineses_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/CANCERS15174263
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00284/ES/CANCER/ es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/MINECO//PIE13%2F00046/ES/Comprehensive, Integrative and Genomic Approach to the Understanding and Treatment of Cancer and Leukemia/ es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica, Técnica y de Innovación 2021-2023/PI22%2F01371/ES/CARACTERIZACIÓN GENÉTICA DE LAS HIPOACUSIAS HEREDITARIAS MEDIANTE LA INTEGRACIÓN DE ESTUDIOS GENÓMICOS Y FUNCIONALES/ es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII//PI22%2F01622es_ES
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional